Back to top
more

CoDiagnostics (CODX)

(Delayed Data from NSDQ)

$1.06 USD

1.06
59,526

0.00 (0.00%)

Updated Jun 4, 2024 03:33 PM ET

After-Market: $1.06 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 249)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CODX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Co-Diagnostics, Inc. [CODX]

Reports for Purchase

Showing records 21 - 40 ( 78 total )

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 21

03/25/2022

Company Report

Pages: 5

Strong Financial Performance in 4Q21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 22

02/04/2022

Company Report

Pages: 5

Hepatitis B Viral Load Test Approved in India; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 23

12/23/2021

Company Report

Pages: 5

Acquisition of All Assets of the Point-of-Care Testing Platform; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 24

12/08/2021

Company Report

Pages: 5

ABC RT-PCR Test Approved in India; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 25

11/30/2021

Company Report

Pages: 5

COVID-19 Assay Performance Unaffected by the New Variant; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 26

11/15/2021

Company Report

Pages: 9

CODX beats 3Q21 Consensus - Advancing POC Diagnostics - Reiterate Buy rating and $29 PT

Provider: Litchfield Hills Research, LLC

Analyst: O'NEILL T

Price: 12.50

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 27

11/12/2021

Company Report

Pages: 5

New Sales Record in 3Q21; Reiterate Buy; Modulating PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 28

10/07/2021

Company Report

Pages: 5

Dengue-Chikungunya Multiplex Test Cleared in India; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 29

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CODX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 30

09/17/2021

Company Report

Pages: 5

Dengue and Chikungunya Tests Cleared in India; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 31

08/13/2021

Company Report

Pages: 6

Record Revenue in 2Q21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 32

07/23/2021

Company Report

Pages: 5

Intellectual Property Portfolio Strengthened; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 33

06/21/2021

Company Report

Pages: 5

COVID-19 Direct Saliva Test Obtains CE Mark; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 34

05/14/2021

Company Report

Pages: 6

Top- and Bottom-Line 1Q21 Beat; Volume Growth to Drive Sales; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 35

03/26/2021

Company Report

Pages: 6

2020 Financial Results Reported; Reiterate Buy; Lowering PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 36

03/03/2021

Company Report

Pages: 6

Point-of-Care COVID-19 PCR Testing Platform in Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 37

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 38

12/15/2020

Company Report

Pages: 6

Sequential Revenue Growth in 4Q20; Reiterate Buy; Raising PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 39

11/17/2020

Company Report

Pages: 6

3Q20 Financial Results Reported; Reiterate Buy; Lowering PT to $29

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Co-Diagnostics, Inc.

Industry: Medical Services

Record: 40

08/31/2020

Company Report

Pages: 6

COVID-19 Testing Market Remains Attractive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party